

Artificial Intelligence and Machine Learning

Businesses adopting artificial intelligence and machine learning technologies and the companies developing them turn to us to navigate regulatory complexities, potential liabilities, and transactional considerations they face on the path to realizing AI's tremendous potential.

We bring together our extensive technical backgrounds and broad range of subject matter experience to help them:

- identify potential risks through data protection impact assessments;
- navigate whether AI's role is categorized as a medical device by the FDA;
- maneuver through ambiguous FDA guidelines related to AI in drug development;
- counsel on the murky landscape of copyright law in connection with generative AI;
- comply with digital communication laws regarding the use of AI systems in content moderation and advertising;
- ensure the use of AI systems is done in an ethical and responsible fashion;
- mitigate risks from contractual, e-discovery, product liability, regulatory, and tort-based claims; and
- complement their businesses and expand into new markets through investments in and acquisitions of sophisticated AI platforms.

From major corporations to emerging growth companies and their investors, we provide this guidance across the full range of AI/ML technologies including:

- fraud detection and digital identity;

Capability Lawyers



Carolyn Zander Alford
Atlanta



John M. Anderson
Atlanta



Lisa M. Dwyer
Washington, D.C.



Amanda J. Klingler
Washington, D.C.



Phyllis B. Sumner
Atlanta



Rose J. Jones
Atlanta

- digital health and personalized medicine;
- chatbots;
- e-commerce and marketplace platforms;
- facial/biometric data recognition;
- intelligent robotics;
- autonomous vehicles;
- data set licensing; and more.

Cases & Deals

August 10, 2021

Equifax to Acquire Appriss Insights for \$1.825 billion

July 15, 2021

HeartFlow To Go Public in SPAC Merger

April 6, 2021

Sidetrade acquires Amalto

[VIEW ALL](#)

Insights

ARTICLE

April 3, 2024

Federal Enforcers Signal Heightened Scrutiny of Algorithm Use to Inform Pricing Decisions

CLIENT ALERT

March 28, 2024

Executive Order Restricts Foreign Access to U.S. Data, Citing National Security Risks

CLIENT ALERT

March 25, 2024

FDA Publishes White Paper on Artificial Intelligence & Medical Products

[VIEW ALL](#)

Events

SPEAKING ENGAGEMENT

May 28, 2024

Kassi Burns to Speak on the Beverly Hills Bar Association's Webinar

SPEAKING ENGAGEMENT

May 14, 2024

Rose Jones to Speak on American Bar Association Webinar

SPEAKING ENGAGEMENT

April 24, 2024

Rose Jones to Speak at the AI Bootcamp

[VIEW ALL](#)

News

IN THE NEWS

April 8, 2024

Lisa Dwyer comments on the FDA's drug center gearing up to issue guidance on use of artificial intelligence to enhance its regulatory decision-making

IN THE NEWS

April 5, 2024

Dan Kahan comments on a new report from the U.S. Treasury Department examining the growing vulnerability of the financial services industry to cyber-enabled fraud perpetrated by bad actors wielding AI tools

IN THE NEWS

March 13, 2024

Lazar Raynal, Michael Lombardo, Julia Barrett, Bob Cooper and Chris Yook counsel Tractable in a trade secrets dispute with CCC Intelligent Solutions before an Illinois federal court

[VIEW ALL](#)
